PRSS2

Summary

PRSS2 (serine protease 2, HGNC:9483) is a protein-coding gene on chromosome 7q34, encoding Trypsin-2 (P07478). In the ileum, may be involved in defensin processing, including DEFA5.

This gene belongs to the trypsin family of serine proteases and encodes anionic trypsinogen. It is part of a cluster of trypsinogen genes that are located within the T cell receptor beta locus. Enzymes of this family cleave peptide bonds that follow lysine or arginine residues. This protein is found at high levels in pancreatic juice and its upregulation is a characteristic feature of pancreatitis. This protein has also been found to activate pro-urokinase in ovarian tumors, suggesting a function in tumor invasion. In addition, this enzyme is able to cleave across the type II collagen triple helix in rheumatoid arthritis synovitis tissue, potentially participating in the degradation of type II collagen-rich cartilage matrix. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 5645 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 2 total
• Phenotypes (HPO): 17
• Druggable target: yes — 12 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_002770

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9483
Approved symbol	PRSS2
Name	serine protease 2
Location	7q34
Locus type	gene with protein product
Status	Approved
Aliases	TRY2
Ensembl gene	ENSG00000275896
Ensembl biotype	protein_coding
OMIM	601564
Entrez	5645

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000539842, ENST00000610835, ENST00000618750, ENST00000632998, ENST00000633969

RefSeq mRNA: 2 — MANE Select: NM_002770 NM_001303414, NM_002770

CCDS: CCDS83235, CCDS83236

Canonical transcript exons

ENST00000539842 — 5 exons

Exon	Start	End
ENSE00002507173	142774356	142774560
ENSE00003721434	142772049	142772208
ENSE00003736987	142773919	142774055
ENSE00003753318	142770970	142771022
ENSE00003783126	142773266	142773519

Expression profiles

Bgee: expression breadth ubiquitous, 125 present calls, max score 100.00.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 43.5792 / max 75717.6810, expressed in 35 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
204926	559.2093	239
81640	43.5792	35
204927	0.6996	7
204932	0.5660	6
204925	0.3121	20
204924	0.1450	17
204929	0.1053	4
204928	0.1007	3
204930	0.0372	2
204922	0.0362	2

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	100.00	gold quality
pancreas	UBERON:0001264	99.98	gold quality
islet of Langerhans	UBERON:0000006	99.94	gold quality
duodenum	UBERON:0002114	99.48	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.48	gold quality
small intestine	UBERON:0002108	95.72	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	93.23	gold quality
fundus of stomach	UBERON:0001160	89.62	gold quality
ectocervix	UBERON:0012249	89.31	gold quality
right coronary artery	UBERON:0001625	88.57	gold quality
body of stomach	UBERON:0001161	88.26	gold quality
lower esophagus mucosa	UBERON:0035834	87.71	gold quality
endocervix	UBERON:0000458	87.55	gold quality
right uterine tube	UBERON:0001302	87.53	gold quality
left uterine tube	UBERON:0001303	87.47	gold quality
right adrenal gland	UBERON:0001233	85.91	gold quality
right lobe of liver	UBERON:0001114	85.53	gold quality
right adrenal gland cortex	UBERON:0035827	84.88	gold quality
stomach	UBERON:0000945	83.68	gold quality
mucosa of stomach	UBERON:0001199	82.82	gold quality
descending thoracic aorta	UBERON:0002345	81.78	gold quality
left ovary	UBERON:0002119	79.52	gold quality
uterine cervix	UBERON:0000002	79.48	gold quality
right ovary	UBERON:0002118	79.30	gold quality
spleen	UBERON:0002106	79.04	gold quality
esophagus mucosa	UBERON:0002469	78.76	gold quality
left adrenal gland	UBERON:0001234	78.34	gold quality
intestine	UBERON:0000160	78.21	gold quality
body of uterus	UBERON:0009853	78.16	gold quality
apex of heart	UBERON:0002098	77.82	gold quality

Single-cell (SCXA)

Detected in 14 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-GEOD-81547	yes	72979.27
E-ENAD-27	yes	21135.44
E-MTAB-5061	yes	19349.34
E-HCAD-31	yes	19051.09
E-GEOD-83139	yes	14918.53
E-CURD-46	yes	13311.91
E-GEOD-76312	yes	2362.67
E-MTAB-8207	yes	869.05
E-MTAB-7407	yes	588.32
E-MTAB-10283	yes	301.24
E-HCAD-6	yes	220.00
E-CURD-98	yes	165.89
E-GEOD-100618	no	7631.26
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 38)

• Results indicate that up-regulation of anionic trypsinogen in pancreatic diseases does not affect physiological trypsinogen activation, but significantly limits trypsin generation under potential pathological conditions. (PMID:12709065)
• High levels of pulmonary trypsin-2 may be associated with the development of bronchopulmonary dysplasia in preterm infants. (PMID:12949286)
• pancreatitis-associated cationic trypsin mutations causes increased transactivation of anionic trypsinogen. (PMID:14695529)
• Expression of trypsinogen 1 and 2 is better preserved than prostate specific antigen in high-grade prostatic neoplasms (PMID:15651064)
• gene conversion between PRSS1 and PRSS2 trypsinogen genes can occur and cause genetically determined chronic pancreatitis (PMID:15776435)
• G191R variant of PRSS2 mitigates intrapancreatic trypsin activity and thereby protects against chronic pancreatitis (PMID:16699518)
• Our results suggest that serum trypsinogen-2 is a most useful marker for diagnosing patients with cholangiocarcinoma, and it is superior to serum CA19-9 and CEA. (PMID:17640760)
• Co-localization of trypsin-2 and MMP-9 resulted in intracellular proMMP-9 processing that represented fully or partially activated MMP-9. (PMID:18062964)
• A loss of function polymorphism (G191R) of anionic trypsinogen (PRSS2) confers protection against chronic pancreatitis. (PMID:18362849)
• Total immunoreactivity of soluble urinary MMP-14 and the levels of trypsin (TRY)-1 and TRY-2, but not of TATI, were also significantly increased in diabetic nephropathy (PMID:18428024)
• A fusion with PRSS1 is associated with hereditary pancreatitis. (PMID:18461367)
• primary role of trypsinogen sulfation in humans is to stimulate autoactivation of PRSS1 (PMID:18986305)
• The p.G191R variant protected against alcoholic and idiopathic chronic pancreatitis as well as alcoholic acute pancreatitis in Japan. (PMID:19052022)
• G191R PRSS2 is a rare allele in the Indian population and the data suggest a nonsignificant trend towards a protective effect from tropical calcific pancreatitis in Indians. (PMID:19077465)
• Results do not support the urinary trypsinogen-2 dipstick test (UTDT) to replace standard plasma amylase for the diagnosis of AP, however, the test demonstrated an adequate sensitivity to be used for rapid early screening of AP in daily clinics. (PMID:19752771)
• Hyperexpression of the PRSS2 gene is associated with pancreatic cancer. (PMID:20428826)
• there was a borderline statistically significant association between pancreatic cancer and HAT/HCT but no association between pancreatic cancer and HAT, HCT. (PMID:20484960)
• Urine trypsinogen-2 test may be an important diagnostic tool in excluding the diagnosis of acute pancreatitis; it has a negative predictive value. (PMID:20517765)
• A genetic variant of PRSS2 may contribute to the low prevalence of pancreatitis in primary hyperparathyroidism patients. (PMID:20625975)
• results suggest that trypsinogen-2 is a more sensitive marker than amylase, and it can be useful in early diagnosis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. (PMID:21792081)
• Data show that urinary trypsinogen-2 dipstick test is a useful test for early diagnosis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. (PMID:21946810)
• Elevation of urine trypsinogen 2 is an independent risk factor for pancreatic fistula after pancreaticoduodenectomy. (PMID:22357509)
• Report a simple, rapid, easy, and noninvasive urinary trypsinogen-2 test can diagnose or rule out most cases of acute pancreatitis. (PMID:22481290)
• trypsin-2 over-expression enhanced tongue carcinoma cell invasion by various genetic and proteolytic mechanisms. (PMID:22909050)
• Two associations with alcoholic pancreatitis at genome-wide significance were identified and replicated at PRSS1-PRSS2 and X-linked CLDN2 through a two-stage genome-wide study. (PMID:23143602)
• Trypsin-1 and trypsin-2 appear to have a function in the degradation of vitreous type II collagen. (PMID:23882137)
• PRSS2 single nucleotide polymorphism associated with the development of alcoholic pancreatitis. (PMID:25253127)
• Serum trypsinogen-2 is associated with pancreatic cancer and pancreatitis. (PMID:25916077)
• evaluated the association of claudin2 and PRSS1-PRSS2 polymorphisms with idiopathic recurrent acute (RAP) and chronic pancreatitis (PMID:26110235)
• Data indicate association between polymorphism rs10273639 of the PRSS1-PRSS2 locus and pancreatitis development. (PMID:27846138)
• Role of the Common PRSS1-PRSS2 Haplotype in Alcoholic and Non-Alcoholic Chronic Pancreatitis: Meta- and Re-Analyses. (PMID:33202925)
• Defective binding of SPINK1 variants is an uncommon mechanism for impaired trypsin inhibition in chronic pancreatitis. (PMID:33515547)
• TATI, TAT-2, and CRP as Prognostic Factors in Colorectal Cancer. (PMID:34794144)
• Trypsinogen (PRSS1 and PRSS2) gene dosage correlates with pancreatitis risk across genetic and transgenic studies: a systematic review and re-analysis. (PMID:35089416)
• Pancreatitis-Associated PRSS1-PRSS2 Haplotype Alters T-Cell Receptor Beta (TRB) Repertoire More Strongly Than PRSS1 Expression. (PMID:36191639)
• PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression. (PMID:36575174)
• High expression of serine protease 2 (PRSS2) associated with invasion, metastasis, and proliferation in gastric cancer. (PMID:37022096)
• PRSS2 regulates EMT and metastasis via MMP-9 in gastric cancer. (PMID:37331089)

Cross-species orthologs

16 orthologs

Organism	Symbol	Gene ID
danio_rerio	prss1	ENSDARG00000042993
mus_musculus	Try5	ENSMUSG00000036938
mus_musculus	Try4	ENSMUSG00000054106
mus_musculus	Prss2	ENSMUSG00000057163
mus_musculus	Prss1l	ENSMUSG00000058119
mus_musculus	Prss1	ENSMUSG00000062751
mus_musculus	Prss3l	ENSMUSG00000071517
mus_musculus	Prss3	ENSMUSG00000071519
mus_musculus	Try10	ENSMUSG00000071521
rattus_norvegicus	Prss2l1	ENSRNOG00000050493
rattus_norvegicus	Prss1	ENSRNOG00000063605
rattus_norvegicus	Prss2	ENSRNOG00000064731
rattus_norvegicus	Try10	ENSRNOG00000070336
rattus_norvegicus		ENSRNOG00000075892
rattus_norvegicus	Prss3	ENSRNOG00000078399
rattus_norvegicus		ENSRNOG00000089144

Paralogs (3): PRSS3 (ENSG00000010438), PLAU (ENSG00000122861), PRSS1 (ENSG00000204983)

Protein

Protein identifiers

Trypsin-2 — P07478 (reviewed: P07478)

Alternative names: Anionic trypsinogen, Serine protease 2, Trypsin II

All UniProt accessions (4): P07478, A0A0J9YYC8, A6XMV9, Q5NV56

UniProt curated annotations — full annotation on UniProt →

Function. In the ileum, may be involved in defensin processing, including DEFA5.

Subcellular location. Secreted. Extracellular space.

Tissue specificity. Expressed in Paneth cells, at the base of small intestinal crypts.

Post-translational modifications. Sulfated on tyrosine. Sulfation at Tyr-154 increases selectivity towards basic versus apolar residues at the P2’ position of inhibitors that bind in a substrate-like fashion. Although the increase in selectivity is relatively small, it may facilitate digestion of a broader range of dietary proteins.

Cofactor. Binds 1 Ca(2+) ion per subunit.

Polymorphism. His-153 variation is a common polymorphism in African populations with a minor allele frequency of 9.2%, it eliminates sulfation at Tyr-154, with no consequences on digestive physiology.

Similarity. Belongs to the peptidase S1 family.

RefSeq proteins (2): NP_001290343, NP_002761* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001254	Trypsin_dom	Domain
IPR001314	Peptidase_S1A	Family
IPR009003	Peptidase_S1_PA	Homologous_superfamily
IPR018114	TRYPSIN_HIS	Active_site
IPR033116	TRYPSIN_SER	Active_site
IPR043504
IPR050127	Serine_Proteases_S1	Family

Pfam: PF00089

UniProt features (19 total): binding site 4, disulfide bond 4, active site 3, sequence variant 2, signal peptide 1, propeptide 1, site 1, modified residue 1, chain 1, domain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7Z9F	X-RAY DIFFRACTION	1.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P07478-F1	92.17	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (4): 194 (required for specificity); 63 (charge relay system); 107 (charge relay system); 200 (charge relay system)

Ligand- & substrate-binding residues (4): 85; 75; 77; 80

Post-translational modifications (1): 154

Disulfide bonds (4): 30–160, 48–64, 171–185, 196–220

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-1442490	Collagen degradation
R-HSA-1462054	Alpha-defensins
R-HSA-1592389	Activation of Matrix Metalloproteinases
R-HSA-6798695	Neutrophil degranulation
R-HSA-6803157	Antimicrobial peptides

MSigDB gene sets: 165 (showing top): MODULE_172, GOBP_DIGESTION, MODULE_52, MODULE_92, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_ANTIMICROBIAL_HUMORAL_RESPONSE, GOMF_METALLOPEPTIDASE_ACTIVITY, GOCC_SECRETORY_GRANULE, GOBP_GROWTH, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, MODULE_66, MODULE_118, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_RUNX1, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_DN

GO Biological Process (7): proteolysis (GO:0006508), digestion (GO:0007586), antimicrobial humoral response (GO:0019730), extracellular matrix disassembly (GO:0022617), positive regulation of cell growth (GO:0030307), collagen catabolic process (GO:0030574), positive regulation of cell adhesion (GO:0045785)

GO Molecular Function (8): metalloendopeptidase activity (GO:0004222), serine-type endopeptidase activity (GO:0004252), calcium ion binding (GO:0005509), serine-type peptidase activity (GO:0008236), protein binding (GO:0005515), peptidase activity (GO:0008233), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (4): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), extracellular matrix (GO:0031012), azurophil granule lumen (GO:0035578)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Degradation of the extracellular matrix	2
Innate Immune System	2
Defensins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of cellular process	2
endopeptidase activity	2
protein metabolic process	1
multicellular organismal process	1
humoral immune response	1
defense response to symbiont	1
cellular component disassembly	1
extracellular matrix organization	1
regulation of cell growth	1
cell growth	1
positive regulation of growth	1
catabolic process	1
collagen metabolic process	1
cell adhesion	1
regulation of cell adhesion	1
metallopeptidase activity	1
serine-type peptidase activity	1
metal ion binding	1
peptidase activity	1
serine hydrolase activity	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
catalytic activity	1
cation binding	1
cellular anatomical structure	1
external encapsulating structure	1
vacuolar lumen	1
secretory granule lumen	1
azurophil granule	1

Protein interactions and networks

STRING

940 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRSS2	MBL2	P11226	991
PRSS2	SERPINA1	P01009	977
PRSS2	SPINK1	P00995	949
PRSS2	CFTR	P13569	707
PRSS2	HTRA1	Q92743	639
PRSS2	COLEC11	Q9BWP8	636
PRSS2	FCN2	Q15485	626
PRSS2	FCN1	O00602	612
PRSS2	CPA1	P15085	602
PRSS2	ACE2	Q9BYF1	591
PRSS2	MORC4	Q8TE76	577
PRSS2	FCN3	O75636	573
PRSS2	CPA2	P48052	552
PRSS2	STATH	P02808	497
PRSS2	CPB1	P15086	489

IntAct

24 interactions, top by confidence:

A	B	Type	Score
PYGO1	BCL9	psi-mi:“MI:0914”(association)	0.700
GSTT1	MID1	psi-mi:“MI:0914”(association)	0.530
SLC35A2	PRSS2	psi-mi:“MI:0915”(physical association)	0.400
TMEM252	PRSS2	psi-mi:“MI:0915”(physical association)	0.400
	ZNF316	psi-mi:“MI:0914”(association)	0.350
PRSS2	GDF11	psi-mi:“MI:0914”(association)	0.350
CIDEC	PRSS2	psi-mi:“MI:0914”(association)	0.350
SYDE1	APBB1	psi-mi:“MI:0914”(association)	0.350
CD8B	PRSS2	psi-mi:“MI:0914”(association)	0.350
PRSS2	POTEF	psi-mi:“MI:0914”(association)	0.350
SLC35A2	PRSS2	psi-mi:“MI:0914”(association)	0.350
DKK2	LRP5	psi-mi:“MI:0914”(association)	0.350
PRSS2	BMP1	psi-mi:“MI:0914”(association)	0.350
BTBD1	IGHA2	psi-mi:“MI:0914”(association)	0.350
FCER1A	PRSS2	psi-mi:“MI:0914”(association)	0.350
FUBP3	PRSS2	psi-mi:“MI:0914”(association)	0.350
PRSS2	FN1	psi-mi:“MI:0914”(association)	0.350
AFG2B	MMP24OS	psi-mi:“MI:0914”(association)	0.350
SF3B1	RBM10	psi-mi:“MI:0914”(association)	0.350
SF3B1	FAM83G	psi-mi:“MI:0914”(association)	0.350
HOXA2	GPX1	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (40): PRSS2 (PCA), TUBB1 (Affinity Capture-MS), PRSS2 (Affinity Capture-MS), PRSS2 (Affinity Capture-MS), PRSS2 (Affinity Capture-MS), ITGA4 (Affinity Capture-MS), PRSS2 (Affinity Capture-MS), GDF11 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), FN1 (Affinity Capture-MS), TUBB3 (Affinity Capture-MS), PRSS2 (Affinity Capture-MS), PRSS2 (Affinity Capture-MS), PRSS2 (Affinity Capture-MS), PRSS2 (Affinity Capture-MS)

ESM2 similar proteins: A0A126GUP6, A0A1S4H5M5, A0A6J1W8N1, B5U2W0, F5HKX0, O19023, O46644, O97366, P00772, P00773, P00774, P05208, P05805, P06871, P06872, P07477, P07478, P08217, P08218, P08419, P08861, P09093, P13582, P16049, P21902, P47796, P55091, P80009, P80010, Q29461, Q2VG86, Q3SYP2, Q49QW1, Q5R1M5, Q7M3E1, Q7M4I3, Q7PEV7, Q7QBP4, Q867B0, Q8I6K0

Diamond homologs: A0A1S4GMJ4, A6NIE9, A8JUP7, G3V801, O08762, O42207, O60235, P00741, P00745, P00762, P00765, P03951, P05049, P07477, P07478, P0CW18, P15120, P16292, P16295, P19799, P29786, P29787, P35030, P35039, P69525, P79953, Q14B25, Q14BX2, Q14C59, Q1JRP2, Q27081, Q28278, Q28315, Q28412, Q29463, Q2KJ63, Q2VG86, Q5G265, Q5U405, Q6BEA2

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
PRSS2	“up-regulates activity”	F2RL1	cleavage

Disease & clinical

Clinical variants and AI predictions

ClinVar

2 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

1607 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:142773497:G:C	W144C	1.000
7:142773497:G:T	W144C	1.000
7:142773384:G:C	D107H	0.999
7:142773385:A:C	D107A	0.999
7:142773385:A:T	D107V	0.999
7:142773495:T:A	W144R	0.999
7:142773495:T:C	W144R	0.999
7:142774360:A:T	D199V	0.999
7:142774366:G:T	G201V	0.999
7:142774478:G:C	W238C	0.999
7:142774478:G:T	W238C	0.999
7:142772151:G:A	C48Y	0.998
7:142772177:T:A	W57R	0.998
7:142772177:T:C	W57R	0.998
7:142772199:G:A	C64Y	0.998
7:142773384:G:T	D107Y	0.998
7:142773385:A:G	D107G	0.998
7:142773498:G:T	G145C	0.998
7:142773975:T:A	C171S	0.998
7:142773976:G:C	C171S	0.998
7:142774018:G:A	C185Y	0.998
7:142774044:G:C	D194H	0.998
7:142774045:A:T	D194V	0.998
7:142774050:T:A	C196S	0.998
7:142774051:G:A	C196Y	0.998
7:142774051:G:C	C196S	0.998
7:142774359:G:C	D199H	0.998
7:142774360:A:C	D199A	0.998
7:142774362:T:C	S200P	0.998
7:142774422:T:A	C220S	0.998

dbSNP variants (sampled 300 via entrez): RS1001237275 (7:142770317 C>A), RS1001472227 (7:142774526 C>T), RS1001882792 (7:142770727 T>C,G), RS1002403925 (7:142771127 A>C,G), RS1003582335 (7:142771353 T>C,G), RS1003583698 (7:142771444 G>C), RS1003962189 (7:142773114 A>C,G), RS1005130051 (7:142771539 A>C,G), RS1005140196 (7:142771783 T>C), RS1005765041 (7:142773362 C>T), RS1006136109 (7:142772401 C>T), RS1006147420 (7:142772727 C>T), RS1006504314 (7:142770781 A>C), RS1007575099 (7:142771958 G>C,T), RS1007657317 (7:142772943 C>G)

Disease associations

OMIM: gene MIM:601564 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

17 total (17 of 17 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000819	Diabetes mellitus
HP:0000952	Jaundice
HP:0001733	Pancreatitis
HP:0001738	Exocrine pancreatic insufficiency
HP:0001945	Fever
HP:0001974	Increased total leukocyte count
HP:0001977	Abnormal thrombosis
HP:0002027	Abdominal pain
HP:0002202	Pleural effusion
HP:0002570	Steatorrhea
HP:0005206	Pancreatic pseudocyst
HP:0005213	Pancreatic calcification
HP:0011227	Elevated circulating C-reactive protein concentration
HP:0012379	Abnormal circulating enzyme concentration or activity
HP:0030247	Splanchnic vein thrombosis
HP:0100027	Recurrent pancreatitis

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001741_1	Pancreatitis	2.000000e-14

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL2095204 (PROTEIN FAMILY), CHEMBL2096988 (SELECTIVITY GROUP), CHEMBL3159 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

12 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 172,350 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1166	ARGATROBAN	4	231
CHEMBL266349	MELAGATRAN	4	5,421
CHEMBL338802	SULFAGUANIDINE	4	4,956
CHEMBL5189739	BEROTRALSTAT	4	7
CHEMBL226335	RUTIN	3	57,988
CHEMBL4112929	MILVEXIAN	3	134
CHEMBL48361	DABIGATRAN	3	13,443
CHEMBL50	QUERCETIN	3	74,559
CHEMBL590799	CAMOSTAT	3	6,733
CHEMBL9509	SILIBININ	3	130
CHEMBL114586	SEPIMOSTAT	2	156
CHEMBL8260	BAICALEIN	2	8,592

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — S1: Chymotrypsin

ChEMBL bioactivities

803 potent at pChembl≥5 of 927 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.52	Ki	0.03	nM	CHEMBL3623792
10.00	Ki	0.1	nM	CHEMBL239127
10.00	Ki	0.1	nM	CHEMBL453539
9.85	IC50	0.14	nM	CHEMBL3980104
9.85	IC50	0.14	nM	CHEMBL3917451
9.80	Ki	0.16	nM	CHEMBL3623793
9.80	Ki	0.16	nM	CHEMBL4483694
9.77	IC50	0.17	nM	CHEMBL3947949
9.77	IC50	0.17	nM	CHEMBL3985298
9.77	IC50	0.17	nM	CHEMBL3972244
9.77	IC50	0.17	nM	CHEMBL3909962
9.74	IC50	0.18	nM	CHEMBL3961130
9.72	IC50	0.19	nM	CHEMBL3951207
9.72	IC50	0.19	nM	CHEMBL3897484
9.72	IC50	0.19	nM	CHEMBL3939171
9.72	IC50	0.19	nM	CHEMBL3969953
9.70	IC50	0.2	nM	CHEMBL3977211
9.68	IC50	0.21	nM	CHEMBL3940399
9.68	IC50	0.21	nM	CHEMBL3917451
9.66	IC50	0.22	nM	CHEMBL3971081
9.64	IC50	0.23	nM	CHEMBL4109828
9.62	IC50	0.24	nM	CHEMBL3953763
9.60	IC50	0.25	nM	CHEMBL3933667
9.59	IC50	0.26	nM	CHEMBL3947460
9.57	IC50	0.27	nM	CHEMBL3962586
9.55	IC50	0.28	nM	CHEMBL4113549
9.55	IC50	0.28	nM	CHEMBL3893507
9.55	IC50	0.28	nM	CHEMBL3893474
9.52	Ki	0.3	nM	CHEMBL2419745
9.52	IC50	0.3	nM	CHEMBL3957994
9.52	IC50	0.3	nM	CHEMBL4106875
9.52	Ki	0.3	nM	CHEMBL420540
9.51	IC50	0.31	nM	CHEMBL3922459
9.51	IC50	0.31	nM	CHEMBL3941889
9.47	IC50	0.34	nM	CHEMBL3977663
9.47	IC50	0.34	nM	CHEMBL3963997
9.46	IC50	0.35	nM	CHEMBL3940716
9.42	IC50	0.38	nM	CHEMBL3962513
9.42	IC50	0.38	nM	CHEMBL3912722
9.41	IC50	0.39	nM	CHEMBL3925221
9.41	IC50	0.39	nM	CHEMBL3941734
9.41	IC50	0.39	nM	CHEMBL3955210
9.40	IC50	0.4	nM	CHEMBL3964583
9.39	IC50	0.41	nM	CHEMBL3985101
9.36	IC50	0.44	nM	CHEMBL3916887
9.35	IC50	0.45	nM	CHEMBL3926197
9.35	IC50	0.45	nM	CHEMBL3940894
9.35	IC50	0.45	nM	CHEMBL3967403
9.35	IC50	0.45	nM	CHEMBL3929693
9.34	IC50	0.46	nM	CHEMBL3979741

PubChem BioAssay actives

741 with measured affinity, of 2156 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(1R,4S,7S,13S,19S,22S,25S,28S,31R,34S,41S,44S,50S)-50-benzyl-4,19-bis[(2S)-butan-2-yl]-25,34-bis[3-(diaminomethylideneamino)propyl]-28-[(1R)-1-hydroxyethyl]-22-(hydroxymethyl)-3,6,12,18,21,24,27,30,33,36,39,43,49,52-tetradecaoxo-54,55-dithia-2,5,11,17,20,23,26,29,32,35,38,42,48,51-tetradecazapentacyclo[29.21.4.07,11.013,17.044,48]hexapentacontane-41-carboxylic acid	1251573: Inhibition of beta-trypsin (unknown origin) using Bz-FVRpNA substrate by spectrophotometry method	ki	<0.0001	uM
2-[(1R,3aS,7S,10S,13S,16S,19S,22S,25R,28S,31S,34S,37S,40S,43R,49S,55S,58R,61S,64R,67S,73S,79S,82R,88S,94S,97S)-10,19,22-tris(4-aminobutyl)-73-(2-amino-2-oxoethyl)-13,61-bis[(2S)-butan-2-yl]-28,31,67-tris(3-carbamimidamidopropyl)-40,97-bis(carboxymethyl)-37,88,94-tris(hydroxymethyl)-79-[(4-hydroxyphenyl)methyl]-55-methyl-16-(2-methylpropyl)-1a,2,4a,8,11,14,17,20,23,26,29,32,35,38,41,44,50,53,56,59,62,65,68,71,74,77,80,83,86,89,92,95,98-tritriacontaoxo-3a-propan-2-yl-7a,8a,11a,12a,15a,16a-hexathia-2a,3,5a,9,12,15,18,21,24,27,30,33,36,39,42,45,51,54,57,60,63,66,69,72,75,78,81,84,87,90,93,96,99-tritriacontazahexacyclo[56.47.4.425,64.443,82.03,7.045,49]heptadecahectan-34-yl]acetic acid	1533293: Inhibition of trypsin (unknown origin)	ki	<0.0001	uM
2-[(1R,4S,7S,13S,19S,22S,25S,28S,31R,34S,40S,43S,49S)-25-(4-aminobutyl)-49-benzyl-4,19-bis[(2S)-butan-2-yl]-34-[3-(diaminomethylideneamino)propyl]-28-[(1R)-1-hydroxyethyl]-22-(hydroxymethyl)-3,6,12,18,21,24,27,30,33,36,39,42,48,51-tetradecaoxo-53,54-dithia-2,5,11,17,20,23,26,29,32,35,38,41,47,50-tetradecazapentacyclo[29.20.4.07,11.013,17.043,47]pentapentacontan-40-yl]acetic acid	1251580: Inhibition of trypsin (unknown origin)	ki	0.0001	uM
2-[(1R,4S,7S,13S,19S,22S,25S,28S,31R,34S,40S,43R,49S)-25-(4-aminobutyl)-49-benzyl-4,19-bis[(2S)-butan-2-yl]-34-[3-(diaminomethylideneamino)propyl]-28-[(1R)-1-hydroxyethyl]-22-(hydroxymethyl)-3,6,12,18,21,24,27,30,33,36,39,42,48,51-tetradecaoxo-53,54-dithia-2,5,11,17,20,23,26,29,32,35,38,41,47,50-tetradecazapentacyclo[29.20.4.07,11.013,17.043,47]pentapentacontan-40-yl]acetic acid	218709: Compound was tested for inhibition of Sunflower beta-trypsin	ki	0.0001	uM
(1R,4S,7S,13S,19S,22S,25S,28S,31R,34S,41S,44S,50S)-50-benzyl-4-[(2S)-butan-2-yl]-25,34-bis[3-(diaminomethylideneamino)propyl]-28-[(1R)-1-hydroxyethyl]-22-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-3,6,12,18,21,24,27,30,33,36,39,43,49,52-tetradecaoxo-54,55-dithia-2,5,11,17,20,23,26,29,32,35,38,42,48,51-tetradecazapentacyclo[29.21.4.07,11.013,17.044,48]hexapentacontane-41-carboxylic acid	1251573: Inhibition of beta-trypsin (unknown origin) using Bz-FVRpNA substrate by spectrophotometry method	ki	0.0002	uM
(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(1S,6S,12S,15S,18S,21S,24S,27S,30R,33S,36S,39S,42S,45S,48R,53S,56S,62S,68S,71R,74S,79S,85S)-6-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-15,24,27-tris(4-aminobutyl)-62-(2-amino-2-oxoethyl)-18,74-bis[(2S)-butan-2-yl]-33,36,68-tris(3-carbamimidamidopropyl)-39,45-bis(carboxymethyl)-42-(hydroxymethyl)-56-[(4-hydroxyphenyl)methyl]-79-methyl-21-(2-methylpropyl)-7,13,16,19,22,25,28,31,34,37,40,43,46,55,58,61,64,67,70,73,76,78,81,84,90-pentacosaoxo-3,4,50,51,92,93-hexathia-8,14,17,20,23,26,29,32,35,38,41,44,47,54,57,60,63,66,69,72,75,77,80,83,89-pentacosazapentacyclo[46.28.14.430,71.08,12.085,89]tetranonacontane-53-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]butanedioic acid	1628817: Inhibition of trypsin (unknown origin) using Bz-FVRpNA as substrate incubated for 30 mins measured for 7 mins by morrison plot analysis	ki	0.0002	uM
2-[[(2S)-1-[(2S)-2-[(5-carbamimidoylthiophen-2-yl)methylcarbamoyl]pyrrolidin-1-yl]-1-oxo-3,3-diphenylpropan-2-yl]amino]acetic acid	766527: Inhibition of human trypsin	ki	0.0003	uM
2-[[(2R)-1-[(2S)-2-[(5-carbamimidoylthiophen-2-yl)methylcarbamoyl]pyrrolidin-1-yl]-1-oxo-3,3-diphenylpropan-2-yl]amino]acetic acid	215245: In vitro inhibition constant (Ki) against human trypsin was determined	ki	0.0003	uM
2-[2-[2-[[2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-[1,3]oxazolo[4,5-c]pyridin-4-yl]amino]ethyl]piperidin-1-yl]acetic acid	254278: Inhibitory constant against trypsin	ki	0.0007	uM
2-[(1R,4S,7S,13S,19S,22S,25S,28S,31R,34S,40S,43S,49S)-49-(2-amino-2-oxoethyl)-4,19-bis[(2S)-butan-2-yl]-25-[3-(diaminomethylideneamino)propyl]-28,34-bis[(1R)-1-hydroxyethyl]-22-(hydroxymethyl)-3,6,12,18,21,24,27,30,33,36,39,42,48,51-tetradecaoxo-53,54-dithia-2,5,11,17,20,23,26,29,32,35,38,41,47,50-tetradecazapentacyclo[29.20.4.07,11.013,17.043,47]pentapentacontan-40-yl]acetamide	1251580: Inhibition of trypsin (unknown origin)	ki	0.0007	uM
[2-[(3,5-dimethyl-1-phenylpyrazol-4-yl)amino]-2-oxoethyl] 2-(6-carbamimidoyl-2-methyl-1H-indol-3-yl)acetate	1387138: Inhibition of trypsin (unknown origin) pre-incubated for 30 mins before N-Boc-FSR-AMC substrate addition and measured after 30 mins	ic50	0.0010	uM
(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]pentanediamide	682988: Tight binding inhibition of human trypsin expressed in Drosophila melanogaster S2 cells using Boc-QAR-AMC as substrate incubated for 15 mins prior to substrate addition measured for 30 mins by fluorimetric analysis	ki	0.0010	uM
ethyl 2-[2-[2-[[2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-[1,3]oxazolo[4,5-c]pyridin-4-yl]amino]ethyl]piperidin-1-yl]acetate	254278: Inhibitory constant against trypsin	ki	0.0013	uM
[4-(diaminomethylideneamino)phenyl] 4-(diaminomethylideneamino)benzoate	1555462: Inhibition of trypsin (unknown origin) using Boc-Val-Pro-Arg-AMC as substrate preincubated with enzyme for 15 mins followed by addition of substrate by fluorescence plate reader analysis	ic50	0.0014	uM
N-[2-(1-benzylpiperidin-2-yl)ethyl]-2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-[1,3]oxazolo[4,5-c]pyridin-4-amine	254278: Inhibitory constant against trypsin	ki	0.0015	uM
2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-N-(2,2-difluoro-2-piperidin-2-ylethyl)-[1,3]oxazolo[4,5-c]pyridin-4-amine	254278: Inhibitory constant against trypsin	ki	0.0015	uM
2-[2-[2-[[2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-[1,3]oxazolo[4,5-c]pyridin-4-yl]amino]ethyl]piperidin-1-yl]ethanol	254278: Inhibitory constant against trypsin	ki	0.0016	uM
2-[[(2R)-1-[(2S)-2-[(5-carbamimidoylthiophen-2-yl)methylcarbamoyl]-2,5-dihydropyrrol-1-yl]-3-cyclohexyl-1-oxopropan-2-yl]amino]acetic acid	264686: Inhibition of trypsin	ic50	0.0016	uM
[4-(aminomethyl)phenyl] 4-(diaminomethylideneamino)benzoate	1555462: Inhibition of trypsin (unknown origin) using Boc-Val-Pro-Arg-AMC as substrate preincubated with enzyme for 15 mins followed by addition of substrate by fluorescence plate reader analysis	ic50	0.0016	uM
2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-N-(2-piperidin-2-ylethyl)-[1,3]oxazolo[4,5-c]pyridin-4-amine	254278: Inhibitory constant against trypsin	ki	0.0016	uM
2-[[(2R)-1-[(2S)-2-[(4-carbamimidoylfuran-2-yl)methylcarbamoyl]-2,5-dihydropyrrol-1-yl]-3-cyclohexyl-1-oxopropan-2-yl]amino]acetic acid	264686: Inhibition of trypsin	ic50	0.0019	uM
(2S)-N-[(2S)-1-(1,3-benzoxazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-(3,3-dimethylbutanoylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid	321200: Inhibition of human trypsin	ic50	0.0023	uM
4-[2-[(2S,11S)-11-(2,3-dihydro-1-benzofuran-5-ylsulfonylamino)-12-oxo-1-azatricyclo[6.4.1.04,13]trideca-4,6,8(13)-trien-2-yl]-2-oxoethyl]piperidine-1-carboximidamide	215553: Inhibitory constant against trypsin determined in Vitro	ki	0.0025	uM
[4-(diaminomethylideneamino)phenyl] 4-aminobenzoate	1555462: Inhibition of trypsin (unknown origin) using Boc-Val-Pro-Arg-AMC as substrate preincubated with enzyme for 15 mins followed by addition of substrate by fluorescence plate reader analysis	ic50	0.0028	uM
2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-N-[2-[1-(2,2-difluoroethyl)piperidin-2-yl]ethyl]-[1,3]oxazolo[4,5-c]pyridin-4-amine	254278: Inhibitory constant against trypsin	ki	0.0029	uM
4-[3-[(3S)-3-(2,3-dihydro-1-benzofuran-5-ylsulfonylamino)-2-oxoazepan-1-yl]-2-oxopropyl]benzenecarboximidamide	215553: Inhibitory constant against trypsin determined in Vitro	ki	0.0032	uM
1-(3-carbamimidoylphenyl)-N-[2-fluoro-4-(2-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazole-5-carboxamide	215244: In vitro activity against human trypsin.	ki	0.0034	uM
3-(3-carbamimidoylphenyl)-N-[4-(2-sulfamoylphenyl)phenyl]triazole-4-carboxamide;2,2,2-trifluoroacetic acid	215413: Binding affinity towards human trypsin	ki	0.0034	uM
[4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate	1555462: Inhibition of trypsin (unknown origin) using Boc-Val-Pro-Arg-AMC as substrate preincubated with enzyme for 15 mins followed by addition of substrate by fluorescence plate reader analysis	ic50	0.0035	uM
3-[[(2R)-1-[[(2S)-3-[3-(aminomethyl)phenyl]-1-[(4-carbamimidoylphenyl)methylamino]-1-oxopropan-2-yl]amino]-1-oxo-5-phenylpentan-2-yl]sulfamoylmethyl]benzoic acid	1626146: Inhibition of trypsin (unknown origin)	ki	0.0036	uM
benzyl N-[(2S)-6-amino-1-[5-[[4-[4-[(2-fluorophenyl)methyl]piperazine-1-carbonyl]phenyl]methyl]-1,2,4-oxadiazol-3-yl]-1-oxohexan-2-yl]carbamate	269676: Inhibition of human trypsin	ki	0.0037	uM
1-(3-carbamimidoylphenyl)-N-[4-(2-sulfamoylphenyl)phenyl]-3-(trifluoromethyl)pyrazole-5-carboxamide	215244: In vitro activity against human trypsin.	ki	0.0039	uM
1-(3-carbamimidoylphenyl)-N-[2-fluoro-4-(2-sulfamoylphenyl)phenyl]-3-(trifluoromethyl)pyrazole-5-carboxamide	215244: In vitro activity against human trypsin.	ki	0.0040	uM
1-(3-carbamimidoylphenyl)-N-[4-(2-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazole-5-carboxamide	215244: In vitro activity against human trypsin.	ki	0.0043	uM
2-[[(1R)-2-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]azetidin-1-yl]-1-cyclohexyl-2-oxoethyl]amino]acetic acid	766527: Inhibition of human trypsin	ki	0.0043	uM
2-(3-carbamimidoylphenyl)-N-[2-fluoro-4-(2-sulfamoylphenyl)phenyl]-5-methylpyrazole-3-carboxamide	215244: In vitro activity against human trypsin.	ki	0.0046	uM
2-[[(2R)-1-[(2S)-2-[(6-carbamimidoyl-3-pyridinyl)methylcarbamoyl]-2,5-dihydropyrrol-1-yl]-3-cyclohexyl-1-oxopropan-2-yl]amino]acetic acid	264686: Inhibition of trypsin	ic50	0.0048	uM
5-[3-[(3S)-3-(2,3-dihydro-1-benzofuran-5-ylsulfonylamino)-2-oxoazepan-1-yl]-2-oxopropyl]thiophene-2-carboximidamide	215553: Inhibitory constant against trypsin determined in Vitro	ki	0.0059	uM
(2S,4R)-1-acetyl-N-[1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-hydroxypyrrolidine-2-carboxamide	320964: Inhibition of human trypsin by chromogenic assay	ki	0.0060	uM
(2R)-2-(benzylsulfonylamino)-N-[2-[(4-carbamimidoylphenyl)methylamino]-2-oxoethyl]-4-(1-oxidopyridin-1-ium-2-yl)butanamide	290692: Inhibition of trypsin	ki	0.0063	uM
1-(3-carbamimidoylphenyl)-N-[4-(2-sulfamoylphenyl)phenyl]tetrazole-5-carboxamide;2,2,2-trifluoroacetic acid	215413: Binding affinity towards human trypsin	ki	0.0064	uM
2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-N-[2-[1-(2,2,2-trifluoroethyl)piperidin-2-yl]ethyl]-[1,3]oxazolo[4,5-c]pyridin-4-amine	254278: Inhibitory constant against trypsin	ki	0.0069	uM
(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(1R,4S,7S,10S,13S,16S,19R,22S,25S,28S,31S,34S,37S,40S,45S,48S,51R,54S,60S,66S,69S,79S,85S)-40-[[(2S)-5-amino-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-5-oxopentanoyl]amino]-22,25-bis(4-aminobutyl)-60-(2-amino-2-oxoethyl)-37-benzyl-31,48-bis[(2S)-butan-2-yl]-13,16,34,54-tetrakis(3-carbamimidamidopropyl)-4,10-bis(carboxymethyl)-7-(hydroxymethyl)-66-[(4-hydroxyphenyl)methyl]-85-methyl-28-(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33,36,39,46,49,52,55,58,61,64,67,74,80,83,86-pentacosaoxo-42,43,71,72,89,90-hexathia-2,5,8,11,14,17,20,23,26,29,32,35,38,47,50,53,56,59,62,65,68,75,81,84,87-pentacosazatetracyclo[43.28.14.419,51.075,79]hennonacontane-69-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]butanedioic acid	1628817: Inhibition of trypsin (unknown origin) using Bz-FVRpNA as substrate incubated for 30 mins measured for 7 mins by morrison plot analysis	ki	0.0069	uM
2-[(aR,1R,3aS,4S,10S,16R,19S,22S,25S,28S,31S,34R,37S,40S,43S,46S,49S,52S,55R,58S,67S,70S,76S,82R,85S,91S,97S)-97-(4-aminobutyl)-91-(2-amino-2-oxoethyl)-28,31,37,40,52-pentakis(3-amino-3-oxopropyl)-58-benzyl-3a,46-bis[(2S)-butan-2-yl]-49-(3-carbamimidamidopropyl)-19,67-bis(carboxymethyl)-22,70,76-tris(hydroxymethyl)-85-[(4-hydroxyphenyl)methyl]-4-methyl-43-(2-methylpropyl)-2a,3,5a,6,9,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,75,78,81,84,87,90,93,96,99-tetratriacontaoxo-7a,8a,11a,12a,15a,16a-hexathia-1a,2,4a,5,8,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80,83,86,89,92,95,98-tetratriacontazapentacyclo[53.50.4.416,82.434,100.010,14]heptadecahectan-25-yl]acetic acid	1533299: Inhibition of trypsin (unknown origin) using Bz-FVR-pNA as substrate preincubated for 30 mins followed by substrate addition and measured for 7 mins by spectrophotometric method	ki	0.0069	uM
2-[2-[(6R,6aR,11bR)-2-carbamimidoyl-6,6a,7,11b-tetrahydro-5H-indeno[2,1-c]quinolin-6-yl]-5-hydroxy-4-methoxyphenyl]benzoic acid	760605: Inhibition of purified human trypsin	ki	0.0075	uM
4-[3-[(3S)-3-(2,3-dihydro-1-benzofuran-5-ylsulfonylamino)-2-oxoazepan-1-yl]-2-oxopropyl]-3-fluorobenzenecarboximidamide	215553: Inhibitory constant against trypsin determined in Vitro	ki	0.0076	uM
(2S)-2-[[(3S,9S,12S,15S,18S,21R,26R,29S,32S)-21-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]-15-(4-aminobutyl)-9-[(2S)-butan-2-yl]-29-[3-(diaminomethylideneamino)propyl]-18-[(1R)-1-hydroxyethyl]-12-(hydroxymethyl)-2,8,11,14,17,20,28,31-octaoxo-23,24-dithia-1,7,10,13,16,19,27,30-octazatricyclo[30.3.0.03,7]pentatriacontane-26-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoic acid	1251573: Inhibition of beta-trypsin (unknown origin) using Bz-FVRpNA substrate by spectrophotometry method	ki	0.0080	uM
4-[3-[(3S)-3-(benzenesulfonamido)-2-oxoazepan-1-yl]-2-oxopropyl]benzenecarboximidamide	215553: Inhibitory constant against trypsin determined in Vitro	ki	0.0083	uM
N-[2-[(5-chloro-2-pyridinyl)carbamoyl]-4-methoxyphenyl]-5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carboxamide	1585403: Inhibition of human trypsin preincubated for 30 mins followed by substrate addition and measured for 20 mins	ic50	0.0091	uM
3-butyl-1-(3-carbamimidoylphenyl)-N-[4-(2-sulfamoylphenyl)phenyl]pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	215244: In vitro activity against human trypsin.	ki	0.0110	uM

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	increases expression, decreases reaction, affects expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
sodium arsenate	decreases expression, increases abundance	1
terbufos	increases methylation	1
trichostatin A	affects expression, decreases reaction	1
cobaltous chloride	increases expression	1
butyraldehyde	increases expression	1
mercuric bromide	affects cotreatment, increases expression	1
S 1 (combination)	increases response to substance	1
vandetanib	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
perfluorohexanesulfonic acid	affects expression	1
dorsomorphin	affects cotreatment, increases expression	1
Bortezomib	decreases expression	1
Temozolomide	decreases expression	1
Arsenic Trioxide	affects expression	1
Arbutin	decreases expression	1
Arsenic	decreases expression, increases abundance	1
Atrazine	decreases expression	1
Fonofos	increases methylation	1
Endosulfan	increases expression	1
Estradiol	decreases expression	1
Fluorouracil	affects expression	1
Parathion	increases methylation	1
Silicon Dioxide	decreases expression	1
Tretinoin	decreases expression	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	decreases expression	1

ChEMBL screening assays

386 unique, capped per target: 335 binding, 51 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1006751	Binding	Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA	Effects of flavonoids isolated from scutellariae radix on fibrinolytic system induced by trypsin in human umbilical vein endothelial cells. — J Nat Prod
CHEMBL4320630	ADMET	Stability of the compound assessed as trypsin (unknown origin)-mediated compound hydrolysis after 8 hrs by SDS-PAGE analysis	Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.